Juli 2022: On July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing a next-generation chimeric antigen receptor (CAR)-T cell therapy platform targeting solid cancer, announced that they had entered into a strategic partnership MOU concerning the development of a new CAR-T cell therapies. The MOU was in regard to the development of new CAR-T cell therapies. Through the use of this memorandum of understanding (MOU), GenScript ProBio and ACT Therapeutics have come to an agreement to further their collaboration in the field of cell therapy.
ACT Therapeutics dan GenScript ProBio sedang dalam proses penandatanganan kontrak untuk pengembangan dan produksi vektor plasmid dan virus untuk pipa pertama ACT Therapeutics' Advanced CAR-T Platform (platform ACT), yang juga akan ditugaskan untuk memproduksi bahan baku untuk saluran pipa ACT Therapeutics berikutnya. Kontrak tersebut akan mencakup produksi plasmid dan vektor virus untuk jalur pertama Platform CAR-T Lanjutan ACT Therapeutics.
Sebagai hasil dari perjanjian ini, GenScript ProBio telah diangkat ke status mitra global yang mampu mendukung platform ACT untuk terapi ACT.
Platform ACT adalah teknologi terapi sel dan gen generasi berikutnya yang menargetkan antigen kanker dengan memasukkan gen yang dirancang untuk menargetkan antigen tersebut ke dalam sel kekebalan. Gen-gen ini dikirim ke sel-sel kekebalan melalui penggunaan vektor virus. GenScript ProBio memiliki pengembangan proses vektor virus berkualitas tinggi dan platform layanan satu atap untuk produksi GMP, yang keduanya diperlukan untuk pengembangan terapi sel dan gen.
ACT Therapeutics’ ACT platform is an advanced CAR-T technology that has a next-generation structure that goes beyond the second-generation CAR-T cell therapy and targets existing kanker darah. This is accomplished by overcoming the immune suppression microenvironment of solid cancer and activating the immune cells that are surrounding the cancer. Several studies have also used animals to test the ACT platform to see how well it works and if it is safe. These studies have also confirmed that the platform can be used to treat solid cancer while staying in the immunosuppressive environment of that cancer. Additionally, it complements the shortcomings of the existing second-generation CAR-T, which makes it a competitive technology for the treatment of solid cancer.
ACT Therapeutics is a Korean bio venture company that has received initial investment through DAYLI Partners, Korea’s leading bio and healthcare venture capital, since its establishment in 2020, and has been recognized for its technology such as receiving pre-series A investment in Samho Green Investment. DAYLI Partners is Korea’s leading bio and healthcare venture capital since its establishment in 2020. At the moment, investment consultations are being held with various securities firms and venture capital companies in order to entice Series A investment.
Brian H. Min, CEO of GenScript ProBio, said, “We are very happy to cooperate with ACT therapeutics in strategic partnership, and we are looking forward to support ACT Therapeutics’ ACT platform as a global partner through our accumulated technology.”
Seogkyoung-Kong, CEO ACT Therapeutics, mengatakan, “Kami telah menyelesaikan persiapan platform ACT untuk muncul secara global melalui kemitraan strategis dengan GenScript ProBio. Kami akan mempercepat pengembangan perawatan yang menargetkan kanker padat yang sulit disembuhkan dan sulit disembuhkan.”
Tentang GenScript ProBio
GenScript ProBio is a subsidiary of GenScript Biotech Corporation, proactively providing end-to-end CDMO service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in cell and gene therapy (CGT), vaccine discovery, biologics discovery and antibody protein drug development to accelerate drug development for customers. GenScript ProBio has established companies in the United States, the Netherlands, South Korea, Shanghai, Hong Kong, Nanjing and other places to serve global customers, and supported customers in the United States, Europe, Asia Pacific and other regions to obtain more than 30 IND approvals.
Menuju misi "Inovasi melalui Kolaborasi", GenScript ProBio berkomitmen untuk membantu pelanggan mempersingkat waktu pengembangan obat biologis dari penemuan hingga komersialisasi, secara signifikan menurunkan biaya R&D dan membangun masa depan yang lebih sehat.
